MedPath

Prospective study about the improvement of therapeutic invasiveness by oral intake of branched-chain amino acid (BCAA) supplement in hepatocellular carcinoma (HCC) patients after transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA)

Not Applicable
Recruiting
Conditions
Hepatocellular carcinoma
Registration Number
JPRN-UMIN000004624
Lead Sponsor
Department of Gastroenterology, Kobe University Graduate School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
150
Inclusion Criteria

Not provided

Exclusion Criteria

Those who had refractory ascites, overt hepatic encephalopathy, uncontrolled esophageal varices, severe jaundice, Child's grade C and portal vein trunk thrombosis were excluded from the study. In addition, those who used intravenous albumin regularly were also excluded.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath